
Parkinson’s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment for Parkinson disease is limited with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of Parkinson disease such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of Parkinson disease pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of Parkinson disease without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of treatment for Parkinson is likely to be cured. Discovered in the 1960s, levodopa was the first symptomatic treatment for Parkinson disease, followed by the availability of dopamine agonists and monoamine oxidase B inhibitors. Until recently, the decision regarding which Parkinson’s treatment is initiated. It is nothing but the Magnetic resonance–guided focused ultrasound (MRgFUS) has been used extensively to ablate brain tissue in movement disorders, such as essential tremor. The treatment for Parkinson disease is done under Magnetic Resonance Imaging guidance which provides real-time imaging and temperature monitoring. Royal Care Super Speciality Hospital is the only Neuro-Care center in all of India, facilitated with expertise and technology that provides an MRgFUS (Magnetic Resonance guided Focused Ultrasound) therapy to Essential Tremors and Parkinson’s patients with tremors.

